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Abstract
Background: It was speculated that fatty tissue originated adipo-
cytokines may play role in pathogenesis of atherosclerosis. These 
adipocytokines may alter vascular homeostasis by effecting endo-
thelial cells, arterial smooth muscle cells and macrophages. Vaspin 
is a newly described member of adipocytokines family. We aimed 
to investigate whether plasma vaspin level has any predictive value 
in coronary artery disease (CAD).
Methods: Forty patients who have at least single vessel ≥ 70 % 
stenosis demostrated angiographically and 40 subjects with normal 
coronary anatomy were included to the study. The vaspin levels 
were measured from serum that is obtained by centrifigation of 
blood and stored at -20 oC by ELISA method. The length, weight 
and body mass index of patients were measured. Biochemical pa-
rameters including total cholesterol, low density lipoprotein, high 
density lipoprotein, creatinine, sodium, potassium, hemoglobine, 
uric acid and fasting glucose were also measured.
Results: Biochemical markers levels were similar in both groups. 
Serum vaspin levels were significantly lower in CAD patients than 
control group (respectively; 256 ± 219 pg/ml vs. 472 ± 564 pg/ml, 
P < 0.02). Beside this serum vaspin level was lower in control group 
with high systolic blood pressure.
Conclusions: Serum vaspin levels were found significantly lower 
in patients with CAD than age-matched subjects with normal coro-
nary anatomy. Vaspin may be used as a predictor of CAD.
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Introduction
Inflammation was thought to be one of the major causes of 
early atherosclerosis and its’ progressive complications such 
as plaque rupture [1, 2]. Inflammation and blood flow are 
alternative pathogenic factors for plaque development [3, 4].
Recently, it was shown that adipokines including visser-
al adipose tissue-derived serine protease inhibitor (VASPIN) 
which have endocrine and local roles in atherosclerosis de-
velopment are syntesized by adipose tissue [5, 6]. Adipose 
tissue derived factors including adipokines has been suggest-
ed as actors for premature and accelerated atherosclerosis in 
obese people [7]. VASPIN is a member of serine protease 
inhibitor family which has a regulator role in glukose and 
lipid metabolism [8]. The high blood vaspin concentration in 
obese subjects was shown [9] and it was also demonstrated 
in both non-obese and obese type 2 diabetic patients [10]. 
The relationship between VASPIN levels and coronary ar-
tery disease (CAD) was unclear in the literature.  
In the present study we aimed to show the relationship 
between  serum  VASPIN  levels  and  patients  with  angio-
graphically proven coronary artery disease.
Methods
In  this  study,  we  screened  40  consecutive  patients  with 
stable angina pectoris who had at least 70% stenosis in any 
coronary artery diagnosed by coronary angiography (CAD 
Group) and 40 subjects with normal coronary anatomy that 
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shown by coronary angiography (Control Group). Exclusion 
criteria consisted acute coronary syndrome, morbid obesity, 
history of diabetes mellitus and coronary artery disease, pa-
tients who had any revascularization theraphy, history of ear-
ly menopause, heart failure and cardiomyopathy. The study 
was approved by the ethical review board of Firat University. 
All patients were informed about the study, and their written 
consent forms were obtained.
Blood samples were obtained within 24 hours of presen-
tation. Blood samples for vaspin (Human Vaspin ELISA Kit, 
ALPCO IMMUNOASSAYS, Catalog Number: 44-VASHU-
E01)) were obtained and centrifuged then stored at -20 oC.   
Serum vaspin levels were analysed after the blood samples 
of all study patients were obtained. BMI was calculated as 
weight divided by heighy squared (kg/m2) according to the 
World Health Organization [11]. 
Table 1. The Demographic Properties of Two Groups
Table 2. The Biochemical Properties of Two Groups
Data expressed as mean ± SD or percentage. P < 0.05 was accepted statistically significant.
Data expressed as mean± SD. P < 0.05 was accepted statistically significant. LDL-C: low density lipoprotein 
cholesterol, HDL-C:  high density lipoprotein cholesterol, Total-C: total cholesterole.
CAD Group (n = 40) Control Group (n = 40) P value
Age (years) 60 ± 11 56 ± 8 0.1
Female (%) 33 43 0.2
Hypertension (%) 48 53 0.4
Hyperlipidemia (%) 55 50 0.4
Smoke (%) 35 23 0.1
Body Mass Index (kg/m2) 26.7 ± 3.6 27 ± 5.4 0.5
Systolic Blood Pressure (mmHg) 122 ± 14 123 ± 15 0.6
Diastolic Blood Pressure (mmHg) 76 ± 8 76 ± 9 0.8
Family History (%) 45 38 0.3
CAD Group (n = 40) Control Group (n = 40) P value
Fasting glucose (mg/dL) 99 ± 23 98 ± 17 0.7
Hemoglobin (g/dL) 13.4 ± 1.2 13.6 ± 3.5 0.7
Creatinin (mg/dL) 1.1 ± 1.0 1.1± 1.3 0.9
Sodyum (mmol/L) 140 ± 4 140 ± 4 0.6
Potasyum (meq/L) 4.3 ± 0.3 4.3 ± 0.3 0.4
Uric acid (mg/dL) 5.6 ± 1.2 6.0 ± 1.7 0.2
Lipid Profile (mg/dL)
LDL-C 123 ± 28 122 ± 26 0.9
HDL-C 41 ± 4 43 ± 6 0.1
Total-C 195 ± 40 193 ± 32 0.6
Vaspin (pg/mL) 256 ± 219 472 ± 564 0.02
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A  conventional  coronary  angiography  was  performed 
with Philips Integris 5000 equipment (Philips Medical Sys-
tems, Best, Netherlands) in patients with stable angina pecto-
ris. After obtaining images by standard approaches, each an-
giogram was interpreted by two independent cardiologists. 
Eighty  patients were divided into two groups according to 
the angiographic properties of their coronary angiographies. 
The CAD group consisted of 40 patients with at least 70% 
stenosis in any coronary artery the control group consisted of 
40 patients with normal coronary anatomy.
Continuous variables were given as mean ± SD; categor-
ical variables were defined as a percentage. A value of P < 
0.05 was considered to be significant. Comparisons between 
the groups were carried out using an independent- samples t-
test. Correlation analyses were performed using the Pearson 
coefficient of correlation. SPSS 15.0 software was used for 




The demographic properties of patients in two groups were 
summarized in Table 1. There were no significant difference 
between groups in age, gender, systolic blood pressure, dia-
stolic blood pressure, body mass index, history of hyperten-
sion, family history, hyperlipidemia and smoke (Table 1). 
The biochemical properties of the study patients were 
seen in Table 2. There were no difference between the groups 
in fasting glucose, hemoglobin, lipid profile, creatinin, so-
dium, potassium and uric acid levels (Table 2). The serum 
VASPIN levels were significantly lower in CAD group than 
control group (256 ± 219 pg/mL and 472 ± 564 pg/mL, re-
spectively, P = 0.02).
There were statistically significant negative correlation 
between serum VASPIN levels and systolic blood pressure 
in control group patients (r:-0.349, P = 0.02). VASPIN levels 
were weakly negative correlated with diastolic blood pres-
sure in control group (r = -0.299, P = 0.06).
Discussion
  
This is the first study demonstrating low serum VASPIN lev-
els in coronary artery disease comparing to the age-matched 
people  with  normal  coronary  anatomy.  We  excluded  the 
subjects with morbid obesity, diabetes mellitus, metabolic 
syndrome, heart failure, previous CAD history which might 
effect the VASPIN levels. According to our study we thought 
that VASPIN may have a protective role for coronary artery 
disease in people.
There were many studies aimed to prevent CAD be-
cause of the mortal complications of CAD and high cost of 
treatment. Even though it was known that inflammation has 
an important role in the both beginning and progression of 
atherosclerotic disease, the biochemical and cellular mecha-
nisms are not clear [12]. The trigger of inflammation is not 
yet understood. In recent years it was shown that adipose 
tissue synthesis many bioactive substances participating into 
the circulation such as adiponectine [5], leptine [13], tumor 
necrosis factor-alfa [14], plasminogen activator inhibitor-1 
[15], interleukine-6 [16], resistine [17], and various growth 
factors  named  adipocines.  These  substances  have  endo-
crine and local effects in atherosclerosis [18]. VASPIN is a 
member of serine protease inhibitor family that have a regu-
latuar role in glucose and lipid metabolism and its’ expres-
sion in visseral adipose tissue in the peak concentration of 
insulin and obesity in Otsuka Long-Evans Tokushima Fatty 
(OLETF) rats was shown [8]. But its’ physiological role is 
stil unknown.
Kadoglou et al. showed the lower vaspin levels in CAD 
compared with healty subjects [19], but in the present study 
we showed the lower VASPIN levels in CAD compared with 
age-matched subjects who had same symptoms with angio-
graphically normal coronary anatomy. Austet et al. could not 
found any relation between serum VASPIN levels and ca-
rotid artery stenosis but they demonstrated that lower serum 
VASPIN levels had correlation with recent ischemic events 
in patients with carotid artery stenosis [17]. So according to 
these studies, we think that the low serum VASPIN levels 
may be a predictor of atherosclerotic disease.
Limitations
Large and long-term follow-up studies are needed. The small 
number of patients was the main limitation of the present 
study. Many risk factors of CAD such as diabetes mellitus, 
obesity might affect the VASPIN levels, so it was difficult to 
use it in all patients in the diagnosis of CAD.
Conclusion
We showed the lower serum VASPIN levels in patients with 
CAD  comparing  to  the  gender  and  age-matched  subjects 
with  angiographically  normal  coronary  anatomy.  So  low 
VASPIN levels may be an indicator of CAD.
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